Loading organizations...
§ Private Profile · Cambridge, MA, USA
Clinical-stage biotech developing bispecific antibodies for inflammatory bowel disease (IBD), targeting TL1A and IL-23p19.
Caldera Therapeutics has raised $37.5M across 1 funding round.
Key people at Caldera Therapeutics.
Caldera Therapeutics has raised $37.5M in total across 1 funding round.
Caldera Therapeutics is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing bispecific antibodies for the targeted treatment of inflammatory bowel disease. The organization's lead clinical candidate, CLD-423, is designed to simultaneously target the TL1A and IL-23p19 pathways in a single molecule to improve therapeutic efficacy. The company licensed this primary asset from Qyuns Therapeutics in April 2025 for a $10 million upfront payment alongside potential future milestone and royalty disbursements. To support ongoing clinical trials, including the dosing of its first healthy volunteers, the firm has raised $112.5 million across Series A and Series A-1 financing rounds. This venture capital backing was provided by a syndicate of prominent institutional investors that includes Atlas Venture, venBio, Omega Funds, and Wellington Management. Currently led by Chief Executive Officer Praveen Tipirneni, Caldera Therapeutics was officially founded in 2025.
Caldera Therapeutics has raised $37.5M across 1 funding round. Most recently, it raised $37.5M Series A in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 14, 2026 | $37.5M Series A | Michelle Doig | Janus Henderson Investors, Wellington Management | Announced |
Key people at Caldera Therapeutics.
Caldera Therapeutics has raised $37.5M in total across 1 funding round.
Caldera Therapeutics's investors include Michelle Doig, Janus Henderson Investors, Wellington Management.
